Novavax
$9.2
1074
-$0.03-0.27% Friday 21:00
Statistics
Day High
9.53
Day Low
9.04
52W High
10.64
52W Low
5.01
Volume
3,288,886
Avg. Volume
4,329,736
Mkt Cap
1.49B
P/E Ratio
3.78
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Dec 7
$2.13
Nov 7
$2.13
Oct 7
$2.13
Sep 7
$2.13
Aug 7
$2.13
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
26FebExpected
Expected EPS
-0.488579
Actual EPS
N/A
Financials
-27.49%Profit Margin
Unprofitable1.36BRevenue
-375MNet Income
Analyst Ratings
$12.83Average Price Target
The highest estimate is 19.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 17%
Sell 17%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow NVAX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Pfizer
PFE
Mkt Cap140.15B
BioNTech
BNTX
Mkt Cap24.99B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Astrazeneca
AZN
Mkt Cap256.58B
Sanofi
SNY
Mkt Cap124.45B
GSK
GSK
Mkt Cap94.51B
Novavax
NVAX
Mkt Cap1.36B
Dynavax Technologies
DVAX
Mkt Cap1.2B
About
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Show more...
CEO
Mr. John Charles Jacobs M.B.A.
Employees
952
Country
US
ISIN
US6700024010
Listings
0 Comments
Share your thoughts
FAQ
What is Novavax stock price today?▼
The current price of NVAX is $9.2 USD — it has decreased by -0.27% in the past 24 hours. Watch Novavax stock price performance more closely on the chart.
What is Novavax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novavax stocks are traded under the ticker NVAX.
Is Novavax stock price growing?▼
NVAX stock has risen by +5.75% compared to the previous week, the month change is a +0.33% rise, over the last year Novavax has showed a +15.14% increase.
What is Novavax market cap?▼
Today Novavax has the market capitalization of 1.49B
When is the next Novavax earnings date?▼
Novavax is going to release the next earnings report on February 26, 2026.
What were Novavax earnings last quarter?▼
NVAX earnings for the last quarter are -1.25 USD per share, whereas the estimation was -1.2 USD resulting in a -4.49% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Novavax revenue for the last year?▼
Novavax revenue for the last year amounts to 1.36B USD.
What is Novavax net income for the last year?▼
NVAX net income for the last year is -375M USD.
Does Novavax pay dividends?▼
Yes, NVAX dividends are paid monthly. The last dividend per share was 2.13 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Novavax have?▼
As of February 23, 2026, the company has 952 employees.
In which sector is Novavax located?▼
Novavax operates in the Health Care sector.
When did Novavax complete a stock split?▼
The last stock split for Novavax was on May 10, 2019 with a ratio of 1:20.
Where is Novavax headquartered?▼
Novavax is headquartered in Gaithersburg, US.